The Core supports the Adult Children Study Program Project Grant (ACS PPG) by recruiting adult children of parents with and without dementia of the Alzheimer type (DAT) for comprehensive clinical and cognitive (psychometric) assessments at entry and every 3 years thereafter (annually for ACS participants >65y). The Core also supplies all Projects with participants. Core data are entered by Core personnel into the database maintained by the Data Management and Statistics (DMS) component of the Administration Core. The Clinical Core interacts directly or indirectly on a daily basis with virtually every facet of the ACS PPG.
The Specific Aims of the Core are to: 1. Recruit, enroll, and maintain the ACS cohort to support the Projects in this application. In each of the first 3 years of the grant, the Core will enroll 80 ACS participants for a total sample of 240 participants. Participants will be recruited in 3 age groups in each of 2 categories: a. Category 1 (total sample = 120 participants): at least one biologic parent with DAT with age at onset (AAO) before 80y: 1) Age group 45-54y (n=40); 2) Age group 55-64y (n=40); 3) Age group 65-74y (n=40). b. Category 2 (total sample = 120 participants): neither biologic parent with DAT (both must be >70y): 1) Age group 45-54y (n=40); 2) Age group 55-64y (n=40); 3) Age group 65-74y (n=40). 2. Comprehensively assess the ACS participants with well-established clinical and cognitive measures every three years (annually for those >65y) and request voluntary permission for autopsy .3. Obtain blood for apolipoprotein E (apoE) genotyping and banking of extracted DNA and plasma (supported by the Genetics Core of the Alzheimer's Disease Research Center). 4. Coordinate the participation of ACS participants in all Projects: Project 1 - Amyloid imaging in the Adult Children Study; Project 2 - CSF markers of antecedent AD; Project 3 - Attentional profiles as an early marker of DAT; Project 4 - Neuroanatomical markers of early AD 5. Integrate all Core data with the DMS component of the Administration Core and interact cooperatively with all components of the PPG.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG026276-02
Application #
7309954
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
2
Fiscal Year
2006
Total Cost
$114,605
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Schindler, Suzanne E; Sutphen, Courtney L; Teunissen, Charlotte et al. (2018) Upward drift in cerebrospinal fluid amyloid ? 42 assay values for more than 10 years. Alzheimers Dement 14:62-70
Sato, Chihiro; Barthélemy, Nicolas R; Mawuenyega, Kwasi G et al. (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 98:861-864
Babulal, Ganesh M; Chen, Suzie; Williams, Monique M et al. (2018) Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. J Alzheimers Dis 66:1213-1221
Millar, Peter R; Balota, David A; Bishara, Anthony J et al. (2018) Multinomial models reveal deficits of two distinct controlled retrieval processes in aging and very mild Alzheimer disease. Mem Cognit 46:1058-1075
Gangishetti, Umesh; Christina Howell, J; Perrin, Richard J et al. (2018) Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. Alzheimers Res Ther 10:98
Vlassenko, Andrei G; Gordon, Brian A; Goyal, Manu S et al. (2018) Aerobic glycolysis and tau deposition in preclinical Alzheimer's disease. Neurobiol Aging 67:95-98
Roe, Catherine M; Babulal, Ganesh M; Stout, Sarah H et al. (2018) Using the A/T/N Framework to Examine Driving in Preclinical AD. Geriatrics (Basel) 3:
Stout, Sarah H; Babulal, Ganesh M; Ma, Chunyu et al. (2018) Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers. Alzheimers Dement 14:610-616
Chen, Jason A; Fears, Scott C; Jasinska, Anna J et al. (2018) Neurodegenerative disease biomarkers A?1-40, A?1-42, tau, and p-tau181 in the vervet monkey cerebrospinal fluid: Relation to normal aging, genetic influences, and cerebral amyloid angiopathy. Brain Behav 8:e00903
Day, Gregory S; Musiek, Erik S; Morris, John C (2018) Rapidly Progressive Dementia in the Outpatient Clinic: More Than Prions. Alzheimer Dis Assoc Disord 32:291-297

Showing the most recent 10 out of 352 publications